The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder
Authors:
- Orli S. SchwartzOSOrli S. Schwartz
- Paul AmmingerPAPaul Amminger
- Bernard T. BauneBBBernard T. Baune
- Gillinder BediGBGillinder Bedi
- Michael BerkMBMichael Berk
- Sue M. CottonSCSue M. Cotton
- Rothanthi Daglas-GeorgiouRDRothanthi Daglas-Georgiou
- Nick GlozierNGNick Glozier
- Ben HarrisonBHBen Harrison
- Daniel F. HermensDaniel F. Hermens
- Emma JenningsEJEmma Jennings
- Jim LagopoulosJLJim Lagopoulos
Open Access
- 24 October 2023
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-19
Abstract
Background: Existing treatments for young people with severe depression have limited effectiveness. The aim of the Study of Ketamine for Youth Depression (SKY-D) trial is to determine whether a 4-week course of low-dose subcutaneous ketamine is an effective adjunct to treatment-as-usual in young people with major depressive disorder (MDD). Methods: SKY-D is a double-masked, randomised controlled trial funded by the Australian Government’s National Health and Medical Research Council (NHMRC). Participants aged between 16 and 25 years (inclusive) with moderate-to-severe MDD will be randomised to receive either low-dose ketamine (intervention) or midazolam (active control) via subcutaneous injection once per week for 4 weeks. The primary outcome is change in depressive symptoms on the Montgomery-Åsberg Depression Rating Scale (MADRS) after 4 weeks of treatment. Further follow-up assessment will occur at 8 and 26 weeks from treatment commencement to determine whether treatment effects are sustained and to investigate safety outcomes. Discussion: Results from this trial will be important in determining whether low-dose subcutaneous ketamine is an effective treatment for young people with moderate-to-severe MDD. This will be the largest randomised trial to investigate the effects of ketamine to treat depression in young people. Trial registration: Australian and New Zealand Clinical Trials Registry ID: ACTRN12619000683134. Registered on May 7, 2019. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377513.Keywords
All Related Versions
Funding Information
- National Health and Medical Research Council (1138736)
- Orygen
This publication has 64 references indexed in Scilit:
- Distinct neurometabolic profiles are evident in the anterior cingulate of young people with major psychiatric disordersTranslational Psychiatry, 2012
- Regionally specific alterations in functional connectivity of the anterior cingulate cortex in major depressive disorderPsychological Medicine, 2012
- The Consensus Sleep Diary: Standardizing Prospective Sleep Self-MonitoringSLEEP, 2012
- In vivo detection of GABA and glutamate with MEGA‐PRESS: Reproducibility and gender effectsJournal of Magnetic Resonance Imaging, 2011
- Recovery and Recurrence Following Treatment for Adolescent Major DepressionArchives of General Psychiatry, 2011
- Long-Term Outcome of Adolescent Depression Initially Resistant to Selective Serotonin Reuptake Inhibitor TreatmentThe Journal of Clinical Psychiatry, 2010
- Increased Anterior Cingulate Cortical Activity in Response to Fearful Faces: A Neurophysiological Biomarker that Predicts Rapid Antidepressant Response to KetamineBiological Psychiatry, 2009
- Consistency and functional specialization in the default mode brain networkProceedings of the National Academy of Sciences, 2008
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979